Key Points
- Merit Medical Systems director Lynne Ward sold 5,000 shares on May 7 at an average price of $62.61, totaling $313,050. After the sale, she still owned 7,809 shares, a 39.04% reduction in her position.
- The company recently beat earnings expectations, reporting $0.94 EPS versus the $0.84 consensus and revenue of $381.88 million, up 7.4% year over year.
- Analysts remain mostly positive despite some target cuts, with a consensus rating of “Moderate Buy” and an average price target of $92.80, though several firms lowered their price objectives after the earnings report.
Merit Medical Systems, Inc. (NASDAQ:MMSI - Get Free Report) insider Brian Lloyd acquired 2,000 shares of Merit Medical Systems stock in a transaction on Thursday, May 7th. The shares were purchased at an average cost of $62.62 per share, for a total transaction of $125,240.00. Following the acquisition, the insider owned 2,000 shares in the company, valued at approximately $125,240. This represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Merit Medical Systems Price Performance
Merit Medical Systems stock opened at $60.31 on Tuesday. The stock has a market cap of $3.60 billion, a price-to-earnings ratio of 26.11, a P/E/G ratio of 1.91 and a beta of 0.58. The company has a quick ratio of 3.46, a current ratio of 5.08 and a debt-to-equity ratio of 0.45. Merit Medical Systems, Inc. has a 12-month low of $59.74 and a 12-month high of $100.19. The business's 50-day simple moving average is $68.73 and its 200 day simple moving average is $79.04.
Merit Medical Systems (NASDAQ:MMSI - Get Free Report) last announced its quarterly earnings data on Thursday, April 30th. The medical instruments supplier reported $0.94 earnings per share for the quarter, beating the consensus estimate of $0.84 by $0.10. Merit Medical Systems had a net margin of 9.03% and a return on equity of 13.54%. The business had revenue of $381.88 million for the quarter, compared to analyst estimates of $377.59 million. During the same period in the prior year, the business posted $0.86 earnings per share. Merit Medical Systems's revenue was up 7.4% compared to the same quarter last year. Merit Medical Systems has set its FY 2026 guidance at 4.010-4.150 EPS. As a group, research analysts anticipate that Merit Medical Systems, Inc. will post 3.61 earnings per share for the current year.
Hedge Funds Weigh In On Merit Medical Systems
Several hedge funds and other institutional investors have recently made changes to their positions in MMSI. Tudor Investment Corp ET AL acquired a new position in Merit Medical Systems during the third quarter valued at approximately $2,913,050,000. Wellington Management Group LLP increased its stake in shares of Merit Medical Systems by 377.7% in the third quarter. Wellington Management Group LLP now owns 1,240,509 shares of the medical instruments supplier's stock valued at $103,248,000 after buying an additional 980,823 shares during the period. Norges Bank bought a new position in shares of Merit Medical Systems during the fourth quarter valued at $75,957,000. Thrivent Financial for Lutherans raised its position in Merit Medical Systems by 250.5% during the 3rd quarter. Thrivent Financial for Lutherans now owns 750,066 shares of the medical instruments supplier's stock worth $62,428,000 after purchasing an additional 536,072 shares during the last quarter. Finally, Iron Triangle Partners LP bought a new position in shares of Merit Medical Systems during the fourth quarter worth about $33,992,000. 99.66% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
Several equities research analysts have issued reports on MMSI shares. Piper Sandler lowered their price target on Merit Medical Systems from $106.00 to $96.00 and set an "overweight" rating for the company in a report on Friday, April 17th. Needham & Company LLC cut their price target on shares of Merit Medical Systems from $101.00 to $90.00 and set a "buy" rating on the stock in a research report on Friday, May 1st. Compass Point set a $107.00 target price on shares of Merit Medical Systems in a research note on Monday, April 20th. BTIG Research initiated coverage on Merit Medical Systems in a report on Friday, February 6th. They set a "buy" rating and a $107.00 price target for the company. Finally, Citigroup reiterated an "outperform" rating on shares of Merit Medical Systems in a report on Monday, April 20th. Eight research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Merit Medical Systems presently has a consensus rating of "Moderate Buy" and an average price target of $92.80.
Get Our Latest Stock Analysis on MMSI
About Merit Medical Systems
(
Get Free Report)
Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company's product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.
Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
